佐力药业(300181) - 2024年6月20日投资者关系活动记录表

Hospital Coverage and Market Expansion - The number of hospitals covered by the company's core product, Wuling Capsule, has increased from over 3,000 in 2018 to more than 10,000 currently, with approximately 2,000-3,000 new hospitals added annually [2] - The company's other core products, Bailing Tablets and Lingze Tablets, are also rapidly expanding their hospital coverage [2] - The company plans to leverage its status as a national essential drug and centralized procurement participant to accelerate hospital coverage and deepen market penetration [2] - The national health commission's promotion of tightly-knit county-level medical consortia will help the company expand into county-level hospitals and primary medical institutions [2] Wuling Capsule Market Position and Strategy - Wuling Capsule is a proprietary product with high industry barriers, competing mainly with other traditional Chinese medicine products for calming and sleep disorders [3] - Wuling Capsule has consistently ranked first in terms of drug usage amount and DDDs (Defined Daily Doses) among nine cities and 121 hospitals from 2017 to 2020 [3] - The company aims to increase Wuling Capsule's OTC sales proportion to over 20% by expanding retail pharmacy coverage and conducting community health activities [3][4] - Wuling Capsule is included in 67 clinical guidelines, expert consensuses, and monographs, enhancing its brand influence [3] Production Capacity and Future Growth - The company's current production capacity is sufficient, with plans for technological upgrades and intelligent transformation to expand capacity [4] - The annual production of Wuling Capsule's key ingredient, Wuling fungus powder, will increase from 600 tons to 900 tons after the completion of the fundraising project [4] - Future growth will be driven by the conversion to larger packaging in existing hospitals and the development of new hospitals in previously under-covered provinces [4] - The national health commission's detailed assessment of essential drug prescription ratios in public hospitals will benefit the sales of essential drugs like Wuling Capsule [4] Research and Development - The company is conducting secondary development of Wuling Capsule and researching its potential in treating mild cognitive impairment (MCI) [5] - Wuling Capsule's indication for "forgetfulness" in its instructions supports its use in preventing or delaying Alzheimer's disease (AD) through early screening and treatment [5] - The company aims to leverage traditional Chinese medicine's "preventive treatment" advantage in the growing market for MCI and AD prevention [5]